Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRongrong Zhou
About this trial
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).
The main questions it aims to answer are:
* Does Cadonilimab combined with SRT in the second-line treatment of brain metastases provide better results? * Is the toxicity of Cadonilimab combined with SRT manageable in second-line treatment of brain metastases? Researchers will compare evaluate the efficacy and safety of Cadonilimab combined with SRT as a second-line treatment for patients with advanced NSCLC： * Receive Cadonilimab combined with SRT for brain lesions. * Visit the hospital regularly once every 12 weeks for checkups and tests
Eligibility criteria
Qualifiers
18 years old ≤ 75 years old; Both male and female;
ECOG 0-1;
Histologically or cytologically confirmed non-small cell lung cancer;
Progression with brain metastasis after previous first-line anti-tumor therapy;
Disqualifiers
Experienced grade 3-4 intracranial toxicity (pituitary or central nervous system toxicity);
No measurable intracranial metastatic lesions without radiotherapy;
Meningeal metastasis;
If receiving chemotherapy or targeted therapy, the washout period should not exceed 3 weeks; if receiving brain metastasis resection, the washout period should not exceed 2 weeks;
Trial design
Treatments tested in this trial
- Cadonilimab combined with SRS
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Rongrong Zhou
Lead sponsor
Xiangya Hospital of Central South University
Sponsor institution
Source ClinicalTrials.gov